نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - ornidazole 500mg;   - film coated tablet - 500 mg - active: ornidazole 500mg   excipient: hypromellose 60 sh hypromellose 6 cp magnesium stearate maize starch microcrystalline cellulose purified talc titanium dioxide - bacterial vaginosis (non-specific vaginitis).

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - ethinylestradiol 0.02mg; levonorgestrel 0.1mg - film coated tablet - 0.1mg/0.02mg - active: ethinylestradiol 0.02mg levonorgestrel 0.1mg excipient: calcium carbonate   carnauba wax croscarmellose sodium glycerol     iron oxide red   iron oxide yellow   isopropyl alcohol lactose monohydrate macrogol 6000   magnesium stearate microcrystalline cellulose povidone       purified talc     purified water sucrose   titanium dioxide   calcium carbonate   carnauba wax glycerol     iron oxide yellow   lactose monohydrate macrogol 6000   magnesium stearate maize starch povidone       purified talc     purified water     sucrose   titanium dioxide   - oral contraception

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - bezafibrate 200mg; bezafibrate 200mg - film coated tablet - 200 mg - active: bezafibrate 200mg excipient: colloidal silicon dioxide macrogols magnesium stearate maize starch microcrystalline cellulose opadry white polyvinyl alcohol purified talc sodium starch glycolate starch titanium dioxide active: bezafibrate 200mg excipient: colloidal silicon dioxide kaolin lactose monohydrate macrogols magnesium stearate maize starch methacrylic acid copolymer microcrystalline cellulose polysorbate 80 purified talc sodium citrate dihydrate sodium starch glycolate titanium dioxide - - primary hyperlipidaemia types iia, iib, iii, iv and v (fredrickson classification) corresponding to groups i, ii and iii of the european atherosclerosis society guidelines – when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response. - secondary hyperlipidaemias, e.g. severe hypertriglyceridemias, when sufficient improvement does not occur after correction of the underlying disorder (e.g. diabetes mellitus).

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - bezafibrate 400mg - modified release tablet - 400 mg - active: bezafibrate 400mg excipient: colloidal silicon dioxide hypromellose   lactose monohydrate   macrogol 10000 magnesium stearate polymethyl methacrylate polysorbate 80 povidone purified talc sodium citrate dihydrate sodium laurilsulfate titanium dioxide

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - tramadol hydrochloride 50mg;   - capsule - 50 mg - active: tramadol hydrochloride 50mg   excipient: colloidal silicon dioxide gelatin   indigo carmine methyl parahydroxybenzoate e218   propyl parahydroxybenzoate e216   iron oxide yellow   magnesium stearate microcrystalline cellulose sodium laurilsulfate   sodium starch glycolate titanium dioxide   water   - relief of moderate to severe pain.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - dasatinib, quantity: 100 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; hyprolose; titanium dioxide; hypromellose; triacetin - dasatinib is indicated for the treatment of adults aged 18 years or over with: ? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. ? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. ? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy. ? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib is indicated for the treatment of paediatric patients with: ? ph+ cml in the chronic phase. ? newly diagnosed ph+ all in combination with chemotherapy.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - dasatinib, quantity: 20 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; hyprolose; croscarmellose sodium; lactose monohydrate; titanium dioxide; hypromellose; triacetin - dasatinib is indicated for the treatment of adults aged 18 years or over with: ? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. ? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. ? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy. ? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib is indicated for the treatment of paediatric patients with: ? ph+ cml in the chronic phase. ? newly diagnosed ph+ all in combination with chemotherapy.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - dasatinib, quantity: 70 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; hyprolose; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; triacetin - dasatinib is indicated for the treatment of adults aged 18 years or over with: ? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. ? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. ? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy. ? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib is indicated for the treatment of paediatric patients with: ? ph+ cml in the chronic phase. ? newly diagnosed ph+ all in combination with chemotherapy.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - dasatinib, quantity: 50 mg - tablet, film coated - excipient ingredients: lactose monohydrate; hyprolose; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin - dasatinib is indicated for the treatment of adults aged 18 years or over with: ? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. ? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. ? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy. ? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib is indicated for the treatment of paediatric patients with: ? ph+ cml in the chronic phase. ? newly diagnosed ph+ all in combination with chemotherapy.

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lisinopril dihydrate 10.89mg equivalent to lisinopril 10 mg;  ;  ;   - tablet - 10 mg - active: lisinopril dihydrate 10.89mg equivalent to lisinopril 10 mg       excipient: calcium hydrogen phosphate dihydrate ferric oxide red (ci77491) magnesium stearate maize starch mannitol - lisinopril is indicated in the treatment of essential hypertension and in renovascular hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents.